Galmed Pharmaceuticals Ltd.
For the period ended Jun 8, 2026. Filed Jun 8, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Jun 8, 2026 · Filed Jun 8, 2026
Use the contents to explore the available documents and sections.
Contents
Introductory Note
This Report on Form 6-K is being filed by Galmed Pharmaceuticals Ltd., an Israeli company ( “Galmed”, “we,” or “us,”) to provide an update regarding our acquisition of Colospan Ltd., a company organized under the laws of the State of Israel (“Colospan”) and certain information regarding Colospan’s business, operations, management, and strategic direction. In connection with Colospan’s business described in this report on Form 6-K, shareholders are cautioned that an investment in us carries risk, including the “Risk Factors” included in this Report and shareholders are urged to review the business description and the risk factors collectively before making any investment decision.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.